AU6262598A - Anti-viral guanosine-rich tetrad forming oligonucleotides - Google Patents
Anti-viral guanosine-rich tetrad forming oligonucleotidesInfo
- Publication number
- AU6262598A AU6262598A AU62625/98A AU6262598A AU6262598A AU 6262598 A AU6262598 A AU 6262598A AU 62625/98 A AU62625/98 A AU 62625/98A AU 6262598 A AU6262598 A AU 6262598A AU 6262598 A AU6262598 A AU 6262598A
- Authority
- AU
- Australia
- Prior art keywords
- oligonucleotide
- htv
- virus
- oligonucleotides
- viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
- C12N2310/151—Nucleic acids forming more than 2 strands, e.g. TFOs more than 3 strands, e.g. tetrads, H-DNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3737497P | 1997-02-04 | 1997-02-04 | |
US60037374 | 1997-02-04 | ||
US07987574 | 1997-12-09 | ||
US08/987,574 US6150339A (en) | 1993-04-23 | 1997-12-09 | Anti-viral guanosine-rich oligonucleotides |
PCT/US1998/001974 WO1998033807A1 (fr) | 1997-02-04 | 1998-02-03 | Oligonucleotides antiviraux riches en guanosine formant des tetrades |
Publications (1)
Publication Number | Publication Date |
---|---|
AU6262598A true AU6262598A (en) | 1998-08-25 |
Family
ID=26714074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU62625/98A Abandoned AU6262598A (en) | 1997-02-04 | 1998-02-03 | Anti-viral guanosine-rich tetrad forming oligonucleotides |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0971944A4 (fr) |
AU (1) | AU6262598A (fr) |
CA (1) | CA2279488A1 (fr) |
WO (1) | WO1998033807A1 (fr) |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) * | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US4388306A (en) * | 1980-06-04 | 1983-06-14 | Merck & Co., Inc. | Pharmaceutical composition comprising modified polyriboinosinic-polyribocytidylic acid, for induction of interferon in primates |
FR2567892B1 (fr) * | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons |
GB8717430D0 (en) * | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5176996A (en) * | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
US5397702A (en) * | 1989-03-06 | 1995-03-14 | The Regents Of The University Of California | Assay for and treatment of autoimmune diseases |
US5075217A (en) * | 1989-04-21 | 1991-12-24 | Marshfield Clinic | Length polymorphisms in (dC-dA)n ·(dG-dT)n sequences |
US5173426A (en) * | 1989-10-06 | 1992-12-22 | Yale University | DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin |
DE4216134A1 (de) * | 1991-06-20 | 1992-12-24 | Europ Lab Molekularbiolog | Synthetische katalytische oligonukleotidstrukturen |
US5523389A (en) * | 1992-09-29 | 1996-06-04 | Isis Pharmaceuticals, Inc. | Inhibitors of human immunodeficiency virus |
US5567604A (en) * | 1993-04-23 | 1996-10-22 | Aronex Pharmaceuticals, Inc. | Anti-viral guanosine-rich oligonucleotides |
US5591721A (en) * | 1994-10-25 | 1997-01-07 | Hybridon, Inc. | Method of down-regulating gene expression |
WO1997003997A1 (fr) * | 1995-07-19 | 1997-02-06 | Aronex Pharmaceuticals, Inc. | Oligonucleotides antiviraux riches en guanosine |
-
1998
- 1998-02-03 AU AU62625/98A patent/AU6262598A/en not_active Abandoned
- 1998-02-03 EP EP98904843A patent/EP0971944A4/fr not_active Withdrawn
- 1998-02-03 WO PCT/US1998/001974 patent/WO1998033807A1/fr not_active Application Discontinuation
- 1998-02-03 CA CA002279488A patent/CA2279488A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP0971944A4 (fr) | 2005-01-26 |
CA2279488A1 (fr) | 1998-08-06 |
WO1998033807A1 (fr) | 1998-08-06 |
EP0971944A1 (fr) | 2000-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6150339A (en) | Anti-viral guanosine-rich oligonucleotides | |
US6323185B1 (en) | Anti-viral guanosine-rich oligonucleotides and method of treating HIV | |
EP1007657B1 (fr) | Nouveaux oligonucleotides synthetiques specifiques au vih et leurs procedes d'utilisation | |
EP0664833B1 (fr) | Oligonucleotides therapeutiques antiviraux anti-vih et produit pharmaceutique | |
US5523389A (en) | Inhibitors of human immunodeficiency virus | |
Ojwang et al. | T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1 | |
JP2798305B2 (ja) | アンチセンスオリゴヌクレオチドおよびヒト免疫不全ウイルス感染におけるその使用 | |
US6288042B1 (en) | Anti-viral guanosine-rich tetrad forming oligonucleotides | |
WO1994008004A9 (fr) | Oligonucleotides therapeutiques antiviraux anti-vih et produit pharmaceutique | |
WO2005095607A2 (fr) | Oligonucleotides antisens diriges contre le domaine ? du vih | |
AU725936B2 (en) | Anti-viral guanosine-rich oligonucleotides | |
AU6262598A (en) | Anti-viral guanosine-rich tetrad forming oligonucleotides | |
WO1998033807A9 (fr) | Oligonucleotides antiviraux riches en guanosine formant des tetrades | |
Boiziau et al. | A phosphorothioate oligonucleotide blocks reverse transcription via an antisense mechanism | |
Fujihashi et al. | Short, terminally phosphorylated oligoriboguanylic acids effectively inhibit cytopathicity caused by human immunodeficiency virus | |
Agrawal | Antisense oligonucleotide-based therapy for HIV-1 infection from laboratory to clinical trials | |
WO2002068582A2 (fr) | Oligonucleotides a phosphorothioate (p=s) renfermant des nucleotides modifies par des azasucres hexagonaux et leur utilisation dans une therapie contre le sida | |
WO1998003646A1 (fr) | Compositions et procedes therapeutiques pour le traitement chez l'homme de maladies ou de troubles lies a l'expression de genes specifiques | |
Galderisi et al. | Antisense oligonucleotides as drugs for HIV treatment | |
WO1997048795A2 (fr) | Compositions et methodes pour traiter des maladies et des troubles lies a l'expression de genes specifiques chez l'homme | |
CA2396240A1 (fr) | Methodes d'inhibition/traitement d'infections par le vih et de symptomes lies au sida | |
EP1007656A1 (fr) | Oligonucleotides modifies specifiques de la proteine kinase a et methodes d'utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |